AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3316312 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 79
Study 3316312 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam + Desipramine (ALP-DMI)
Number of subjects: 79
Study 31355939 — intervention group
Group type: EXPERIMENTAL
Intervention: modified figure-of-eight (mFoE) suture
Number of subjects: 150
Study 31355939 — intervention group
Group type: COMPARATOR
Intervention: standard figure-of-eight (sFoE) suture
Number of subjects: 150
Study 28666993 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin use in patients without HF (20% of 8,981 patients)
Number of subjects: 21105
Study 28666993 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin use in patients with HF (37% of 12,124 patients)
Number of subjects: 21105
Study 26955702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration combined with hemoabsorption
Number of subjects: 60
Study 23743017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration 135 mmol/L
Number of subjects: 10
Study 23743017 — intervention group
Group type: COMPARATOR
Intervention: Dialysate sodium concentration 145 mmol/L
Number of subjects: 10
Study 22059307 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 75-minute play program throughout the school year
Number of subjects: 86
Study 22059307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 18272271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 1g/day for 4 days
Number of subjects: 70
Study 18272271 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 40 mg/day for 4 days
Number of subjects: 70
Study 16982276 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 0
Study 16982276 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/MTAD
Number of subjects: 0
Study 16982276 — intervention group
Group type: COMPARATOR
Intervention: NaOCl (positive control)
Number of subjects: 0
Study 16982276 — intervention group
Group type: COMPARATOR
Intervention: Autoclaved dentin disks (negative control)
Number of subjects: 0
Study 14999162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 118
Study 12488233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oroenteral diets (oral drinks or duodenal infusions of complex formula)
Number of subjects: 27
Study 12488233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous feeding
Number of subjects: 27
Study 12488233 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula (duodenal infusion)
Number of subjects: 27
Study 12488233 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 27
Study 10773013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 18
Study 10773013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem
Number of subjects: 18
Study 10773013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8650464 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (mean = 0.5 mg/day)
Number of subjects: 10
Study 8650464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1617042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 0
Study 1617042 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 0
Study 1617042 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 3158125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg, long‐acting preparation)
Number of subjects: 35
Study 3158125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 35
Study 3158125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 35
Study 3158125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Acebutolol
Number of subjects: 35
Study 30882644 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality immersive training with computerized cognitive therapy (experimental group)
Number of subjects: 42
Study 30882644 — intervention group
Group type: COMPARATOR
Intervention: Computerized cognitive therapy (control group)
Number of subjects: 42
Study 29107496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active robotic total hip arthroplasty (THA)
Number of subjects: 0
Study 29107496 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual technique
Number of subjects: 0
Study 26678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) group
Number of subjects: 95
Study 26678427 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (CHG) group
Number of subjects: 95
Study 26678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study 24727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 g at weeks 0 and 2)
Number of subjects: 120
Study 24727841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120
Study 22543117 — intervention group
Group type: EXPERIMENTAL
Intervention: loose (125)I seeds with automated seed delivery system and real‐time intraoperative planning
Number of subjects: 495
Study 20571129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnitude, high frequency mechanical stimulation (active treatment)
Number of subjects: 174
Study 20571129 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 174
Study 18612883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUPRO, 300 mg/day)
Number of subjects: 40
Study 18612883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 40
Study 16336425 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 16336425 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 0
Study 16336425 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 0
Study 12242194 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational course (Group 1)
Number of subjects: 64
Study 12242194 — intervention group
Group type: COMPARATOR
Intervention: Printed educational material (Group 2)
Number of subjects: 64
Study 10094124 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuroimaging data
Number of subjects: 0
Study 7594332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 30 mg twice daily of lansoprazole
Number of subjects: 10
Study 7594332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drip infusion of 30 mg twice daily of lansoprazole
Number of subjects: 10
Study 7594332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 60 mg once daily of lansoprazole
Number of subjects: 10
Study 7594332 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus injection (30 mg twice daily) vs intravenous bolus injection (60 mg once daily)
Number of subjects: 10
Study 7594332 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus injection vs intravenous drip infusion
Number of subjects: 10
Study 2302074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate (LA) bath (Na, 138; K, 1.5; Ca, 1.75; Mg, 0.75; Cl, 109.5; AC, 17.5; and D,L‐lactate, 17.5 mmol/L)
Number of subjects: 14
Study 2302074 — intervention group
Group type: COMPARATOR
Intervention: Acetate (AC) bath (35 mmol/L)
Number of subjects: 14
Study 6448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.7 microgram/kg)
Number of subjects: 15
Study 6448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (7 microgram/kg)
Number of subjects: 15
Study 31106697 — intervention group
Group type: COMPARATOR
Intervention: Bilingual word recognition in white noise
Number of subjects: 0
Study 31106697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual word learning in noise or quiet
Number of subjects: 0
Study 31220935 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature at 20°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 22°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 24°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 26°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 28°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 30°C
Number of subjects: 216
Study 31220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature increase
Number of subjects: 216
Study 27767328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate and Vilanterol (FF/VI; 100 μg and 25 μg respectively)
Number of subjects: 16485
Study 27767328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate and Vilanterol (FF/VI)
Number of subjects: 16485
Study 27767328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study 25263076 — intervention group
Group type: EXPERIMENTAL
Intervention: OperaVOX
Number of subjects: 100
Study 22788726 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal with pit and fissure sealant on localized marginal defects (group A: n=43)
Number of subjects: 32
Study 22788726 — intervention group
Group type: COMPARATOR
Intervention: Total restoration replacement (group B: n=40)
Number of subjects: 32
Study 22788726 — intervention group
Group type: COMPARATOR
Intervention: Untreated restorations (group C: n=43)
Number of subjects: 32
Study 21220024 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 100
Study 21220024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19751080 — intervention group
Group type: EXPERIMENTAL
Intervention: experimenter-provided implementation intention
Number of subjects: 248
Study 19751080 — intervention group
Group type: EXPERIMENTAL
Intervention: self-generated implementation intention
Number of subjects: 248
Study 19751080 — intervention group
Group type: COMPARATOR
Intervention: questionnaire plus planning instruction
Number of subjects: 248
Study 19751080 — intervention group
Group type: COMPARATOR
Intervention: questionnaire-only
Number of subjects: 248
Study 19751080 — intervention group
Group type: EXPERIMENTAL
Intervention: self-generated implementation intention (moderated by compliance)
Number of subjects: 248
Study 19751080 — intervention group
Group type: EXPERIMENTAL
Intervention: experimenter-provided implementation intention (comparison with self-generated)
Number of subjects: 248
Study 16925790 — intervention group
Group type: EXPERIMENTAL
Intervention: Apotransferrin (dosage regimens not specified)
Number of subjects: 20
Study 16925790 — intervention group
Group type: EXPERIMENTAL
Intervention: Apotransferrin
Number of subjects: 20
Study 16925790 — intervention group
Group type: COMPARATOR
Intervention: Control (10 consecutive patients)
Number of subjects: 20
Study 15324535 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 49
Study 15324535 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 49
Study 11255425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone, 200 mg 3 times per day (n = 234)
Number of subjects: 474
Study 11255425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 240)
Number of subjects: 474
Study 9663729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 9663729 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate
Number of subjects: 10
Study 9663729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Isosorbide‐5‐mononitrate
Number of subjects: 10
Study 9663729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7811986 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day program (n = 39)
Number of subjects: 53
Study 7811986 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week course (n = 14)
Number of subjects: 53
Study 7811986 — intervention group
Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 53
Study 3078419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade Bretschneider cardioplegia
Number of subjects: 19
Study 3078419 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 19
Study 8373842 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estrogens conjugated with progesterone (Group II)
Number of subjects: 47
Study 8373842 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives (Group III)
Number of subjects: 47
Study 8373842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 47
Study 356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding with small filler particle adhesive
Number of subjects: 42
Study 356618 — intervention group
Group type: COMPARATOR
Intervention: Indirect bonding with larger filler particle adhesive
Number of subjects: 42
Study 356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-backed brackets
Number of subjects: 42
Study 356618 — intervention group
Group type: COMPARATOR
Intervention: Perforated brackets
Number of subjects: 42
Study 31856838 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8848 60 μg
Number of subjects: 0
Study 31856838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27764529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 4000 IU/d for 3 months
Number of subjects: 39
Study 27764529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 39
Study 26160083 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intra-operative injection of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Number of subjects: 70
Study 26160083 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative and two post-operative injections of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Number of subjects: 70
Study 22999893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 120mg/day
Number of subjects: 0
Study 22999893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80mg/day
Number of subjects: 0
Study 22999893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160mg/day
Number of subjects: 0
Study 22999893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21070333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 21
Study 21070333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone butyrate
Number of subjects: 21
Study 21070333 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 21
Study 19107656 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct individual therapy
Number of subjects: 161
Study 19107656 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect individual therapy
Number of subjects: 161
Study 19107656 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct group therapy
Number of subjects: 161
Study 19107656 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect group therapy
Number of subjects: 161
Study 19107656 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy control group
Number of subjects: 161
Study 17306417 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (75 U/axilla)
Number of subjects: 322
Study 17306417 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (50 U/axilla)
Number of subjects: 322
Study 17306417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 14609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethane levels in breath of ADHD patients
Number of subjects: 10
Study 14609313 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 10
Study 14609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Butane levels in breath of ADHD patients
Number of subjects: 10
Study 14609313 — intervention group
Group type: COMPARATOR
Intervention: Butane levels in breath of healthy volunteers
Number of subjects: 10
Study 10890292 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills intervention
Number of subjects: 1396
Study 10890292 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention
Number of subjects: 1396
Study 10890292 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1396
Study 8982417 — intervention group
Group type: EXPERIMENTAL
Intervention: n-docosanol 10% cream (early treatment)
Number of subjects: 63
Study 8982417 — intervention group
Group type: EXPERIMENTAL
Intervention: n-docosanol 10% cream (late treatment)
Number of subjects: 63
Study 8982417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1607535 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (intravenous)
Number of subjects: 0
Study 6374644 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire mesh element within the 'buzzer and pad' enuresis alarm device
Number of subjects: 0
Study 6374644 — intervention group
Group type: COMPARATOR
Intervention: No wire mesh element
Number of subjects: 0
Study 31112062 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Woman's Condom (WC2)
Number of subjects: 287
Study 31112062 — intervention group
Group type: COMPARATOR
Intervention: FC2 female condom
Number of subjects: 287
Study 28686657 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) and probenecid
Number of subjects: 14
Study 28686657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi sessions (8 sessions, one-on-one for group A, online for group B)
Number of subjects: 72
Study 26015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (group A)
Number of subjects: 72
Study 26015075 — intervention group
Group type: COMPARATOR
Intervention: Standard care (group B)
Number of subjects: 72
Study 26015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (both groups)
Number of subjects: 72
Study 26015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment (focus groups at 9 months)
Number of subjects: 72
Study 23628378 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electric nerve stimulation (TENS)
Number of subjects: 50
Study 23628378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular hyaluronic acid (HA)
Number of subjects: 50
Study 21318190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization plus motivational interviewing (IDMI)
Number of subjects: 68
Study 21318190 — intervention group
Group type: COMPARATOR
Intervention: Gamblers Anonymous (GA) referral
Number of subjects: 68
Study 19588640 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical AzA 15% gel and oral doxycycline (100 mg), both twice daily for ≤ 12 weeks
Number of subjects: 172
Study 19588640 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical AzA 15% gel
Number of subjects: 172
Study 19588640 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 172
Study 19588640 — intervention group
Group type: COMPARATOR
Intervention: Both AzA gel and vehicle
Number of subjects: 172
Study 17129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 30
Study 17129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (METH)
Number of subjects: 30
Study 17129610 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (CONT)
Number of subjects: 30
Study 17129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-dependent patients (HDP)
Number of subjects: 30
Study 14706014 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (560 mg/day) plus LHRH agonist
Number of subjects: 57
Study 14706014 — intervention group
Group type: COMPARATOR
Intervention: flutamide (375 mg/day) plus LHRH agonist
Number of subjects: 57
Study 11751195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy simulator training
Number of subjects: 28
Study 11751195 — intervention group
Group type: COMPARATOR
Intervention: Conventional training methods
Number of subjects: 28
Study 9410433 — intervention group
Group type: EXPERIMENTAL
Intervention: Special plastic syringe
Number of subjects: 120
Study 9410433 — intervention group
Group type: COMPARATOR
Intervention: Glass syringe
Number of subjects: 120
Study 9410433 — intervention group
Group type: COMPARATOR
Intervention: Conventional plastic syringe
Number of subjects: 120
Study 9410433 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 8311350 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil (0.4 mg.kg‐1)
Number of subjects: 20
Study 8311350 — intervention group
Group type: COMPARATOR
Intervention: clonidine (2.5 micrograms.kg‐1)
Number of subjects: 20
Study 3610991 — intervention group
Group type: EXPERIMENTAL
Intervention: A-only mode (auditory)
Number of subjects: 15
Study 3610991 — intervention group
Group type: COMPARATOR
Intervention: V-only mode (visual)
Number of subjects: 15
Study 31403536 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Octylcyanoacrylate (OCA)
Number of subjects: 44
Study 31403536 — intervention group
Group type: COMPARATOR
Intervention: 5-0 Fast-Absorbing Gut (FG)
Number of subjects: 44
Study 30786937 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-QW + Pred-26
Number of subjects: 0
Study 30786937 — intervention group
Group type: COMPARATOR
Intervention: PBO + Pred-26
Number of subjects: 0
Study 30786937 — intervention group
Group type: COMPARATOR
Intervention: PBO + Pred-52
Number of subjects: 0
Study 27060705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1391
Study 27060705 — intervention group
Group type: COMPARATOR
Intervention: Multiple-micronutrient (MMN) capsules
Number of subjects: 1391
Study 27060705 — intervention group
Group type: COMPARATOR
Intervention: Iron-folate (IFA) capsules
Number of subjects: 1391
Study 25148075 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviour condition
Number of subjects: 60
Study 25148075 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60